Holen Sie sich die Stockscreener-App
20.98
1.13%
-0.24
Vorhandelsmarkt:
20.64
-0.34
-1.62%
Schlusskurs vom Vortag:
$21.22
Offen:
$21.22
24-Stunden-Volumen:
219.19K
Relative Volume:
0.31
Marktkapitalisierung:
$2.36B
Einnahmen:
$461.26M
Nettoeinkommen (Verlust:
$-175.95M
KGV:
-13.06
EPS:
-1.607
Netto-Cashflow:
$-164.65M
1W Leistung:
-5.24%
1M Leistung:
+2.79%
6M Leistung:
-15.40%
1J Leistung:
-32.21%
1-Tages-Spanne:
$20.84
$21.33
1-Wochen-Bereich:
$20.56
$21.77
52-Wochen-Spanne:
$15.96
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Firmenname
Zai Lab Limited Adr
Sektor
Branche
Telefon
862161632588
Adresse
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
20.98 | 2.36B | 461.26M | -175.95M | -164.65M | -1.607 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-21 | Eingeleitet | Macquarie | Outperform |
| 2021-10-12 | Eingeleitet | Bernstein | Mkt Perform |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-04-15 | Eingeleitet | Guggenheim | Buy |
| 2019-07-12 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-05 | Eingeleitet | Macquarie | Outperform |
| 2019-01-29 | Eingeleitet | Credit Suisse | Outperform |
| 2018-11-21 | Eingeleitet | Jefferies | Buy |
| 2018-06-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Eingeleitet | JP Morgan | Neutral |
| 2017-10-16 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Zai Lab Limited Adr Aktie (ZLAB) Neueste Nachrichten
Zai Lab (ZLAB) Expected to Announce Earnings on Thursday - MarketBeat
Zai Lab (NASDAQ: ZLAB, HKEX: 9688) details 2026 AGM votes on board, pay, 10% mandates - Stock Titan
BofAS Raises Zai Lab (09688.HK) TP to HKD18.6, Rating Neutral - AASTOCKS.com
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call - Yahoo Finance
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After Recent Share Price Momentum Shift - Sahm
Zai Lab (NASDAQ:ZLAB) Trading Down 5.2%Here's What Happened - MarketBeat
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 - BioSpace
Zai Lab Ltd (ADR) stock (CA98959U1084): Why Google Discover changes matter more now - AD HOC NEWS
Zai Lab Ltd stock (US98887Q1040): Is its China oncology focus strong enough to unlock new upside? - AD HOC NEWS
Zai Lab and Amgen Launch Clinical Trial for Lung Cancer Therapy - HarianBasis.co
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas - Business Wire
Zai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
[PRE 14A] Zai Lab Ltd Preliminary Proxy Statement - Stock Titan
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas - GlobeNewswire Inc.
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After New Lung Cancer Trial Progress And Amgen Collaboration - Sahm
Zai Lab (NASDAQ:ZLAB) Insider Rafael Amado Sells 2,739 Shares - MarketBeat
Zai Lab (ZLAB) officer auto-sells ADSs to cover RSU tax obligations - Stock Titan
Zai Lab (NASDAQ: ZLAB) CLO auto-sells 1,224 ADSs to cover RSU tax - Stock Titan
Zai Lab (ZLAB) CEO records small ADS sale to cover tax on RSUs - Stock Titan
Zai Lab (NASDAQ: ZLAB) CFO sells 853 ADSs in tax-related RSU vesting - Stock Titan
Tax-driven Zai Lab (ZLAB) ADS sale reported for company executive - Stock Titan
Zai Lab Ltd (ADR) stock: What investors need to know now - AD HOC NEWS
Zai Lab (NASDAQ: ZLAB) reports 5.74M ADS (57.4M ordinary shares) - Stock Titan
ZLAB (NASDAQ: ZLAB) insider files Form 144 showing 11,580 ADS sales - Stock Titan
[144] Zai Lab Ltd SEC Filing - Stock Titan
ZLAB (NASDAQ: ZLAB) Form 144 shows Rafael Amado sold ADS in Mar–Apr 2026 - Stock Titan
ZLAB (NASDAQ: ZLAB) notices proposed sale of 853 ADS; prior transfers listed - Stock Titan
Yajing Chen Sells 5,199 Shares of Zai Lab (NASDAQ:ZLAB) Stock - defenseworld.net
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer - BioPharma APAC
Zai Lab Limited (9688.HK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Revenue per share of Zai Lab Ltd. Sponsored ADR – FWB:1ZL - TradingView
Zai Lab (NASDAQ:ZLAB) CFO Sells $106,007.61 in Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) Insider Sells $196,029.46 in Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 5,576 Shares - MarketBeat
Rafael Amado Sells 9,910 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Zai Lab (ZLAB) CEO nets shares after RSU vesting and tax sale - Stock Titan
Zai Lab (ZLAB) CFO exercises RSUs, automatic ADS sale for taxes - Stock Titan
Zai Lab (ZLAB) executive sells ADSs to cover tax after RSU vest - Stock Titan
Zai Lab Ltd (ADR) stock: China's biotech powerhouse eyes global gains - AD HOC NEWS
Zai Lab (ZLAB) CLO nets ADSs after RSU vesting and tax sale - Stock Titan
Rafael Amado reports ADS sales for ZLAB (NASDAQ: ZLAB) - Stock Titan
9,614 ADS tied to vesting listed by ZLAB (NASDAQ: ZLAB) with Fidelity broker - Stock Titan
Insider sells ZLAB (NASDAQ: ZLAB) ADS — Form 144 lists 4,194 shares - Stock Titan
Affiliate sale notice: ZLAB (NASDAQ: ZLAB) up to 5,199 ADS - Stock Titan
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy - BioSpace
Zai Lab (NASDAQ:ZLAB) Trading 9.5% HigherStill a Buy? - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Hesai Group Sponsored ADR (NASDAQ:HSAI) Given Consensus Rating of “Buy” by Brokerages - Defense World
Finanzdaten der Zai Lab Limited Adr-Aktie (ZLAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):